EHA 2026: Combination Therapy Provides Durable QoL and Physical Function Benefits in Treatment-Naïve CLL
At EHA 2026, results from the phase 3 AMPLIFY trial showed that time-limited acalabrutinib-based combinations were associated with greater and more durable improvements in quality of life and physical functioning than chemoimmunotherapy.
Relateret indhold
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen